五洲医疗跌0.02%，成交额3120.76万元，今日主力净流入-218.80万

Core Viewpoint - The company, Wuzhou Medical, is engaged in the research, production, and sales of disposable sterile infusion medical devices, benefiting from the depreciation of the RMB and its classification as a "specialized, refined, distinctive, and innovative" enterprise [2][3]. Group 1: Company Overview - Wuzhou Medical specializes in disposable sterile infusion medical devices, including syringes, infusion sets, blood transfusion sets, and other related medical supplies [2]. - The company was established on April 15, 2011, and went public on July 5, 2022, with its main revenue sources being syringes (41.29%), medical puncture needles (25.51%), and infusion/blood transfusion devices (20.92%) [7]. - As of October 20, the number of shareholders increased by 17.31% to 5,489, while the average circulating shares per person decreased by 14.76% [7]. Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical reported a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, down 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Dynamics - The company has a high overseas revenue ratio of 96.88%, benefiting from the depreciation of the RMB [3]. - The stock experienced a slight decline of 0.02% on December 25, with a trading volume of 31.21 million yuan and a turnover rate of 1.87%, leading to a total market capitalization of 2.827 billion yuan [1].